NCT Number: NCT07448337
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:
What are the demographic and clinical characteristics and severity profiles of psoriasis patients?
What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?
Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Trial opening soon.
Get Notified12 year and older
All sexes
Observational
San José, Provincia de San José, 40901, Costa Rica
Benjamin Hidalgo-Matlock, Dermatologist
SUB_INVESTIGATOR
Daniel E Barquero-Orias, Dermatologist
CONTACT
Daniel E Barquero-Orias, Dermatologist
SUB_INVESTIGATOR
Pamela Cambronero-Ulate, Dermatology Resident
PRINCIPAL_INVESTIGATOR
Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2024-2025
Proportion (%) of patients with documented diagnosis of obesity (BMI ≥30 kg/m²), diabetes mellitus (prior diagnosis or HbA1c ≥6.5%), hypertension (prior diagnosis or BP ≥140/90 mmHg), dyslipidemia (prior diagnosis or abnormal lipid profile), and metabolic syndrome.
Time frame: 2024-2025
Proportion (%) of patients with documented history of coronary artery disease, myocardial infarction, angina/revascularization, ischemic stroke, or peripheral arterial disease.
Time frame: 2024-2025
Proportion (%) of patients with rheumatologist-confirmed diagnosis of psoriatic arthritis, including characterization of predominant clinical domain (peripheral arthritis, axial involvement, enthesitis, dactylitis).
Time frame: 2024-2025
Psoriasis Area and Severity Index (PASI), continuous score (0-72), categorized as mild (<10), moderate (10-20), or severe (>20).
Time frame: 2024-2025
Body Surface Area (BSA) Affected, percentage of body surface area affected by psoriasis
Time frame: 2024-2025
Statistical association between severity categories and presence of metabolic comorbidities, atherosclerotic disease, and psoriatic arthritis using chi-square, Fisher's exact test, t-test or Mann-Whitney U test.
Time frame: 2024-2025
Continuous values of C-reactive protein, erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, cardiac troponin, B-type natriuretic peptide, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total bilirubin.
Contact information is provided by the study sponsor or research team.
Caja Costarricense de Seguro Social
Other Gov
Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07448402
Psoriasis, Psoriasis (PsO)
San José, Provincia de San José, Costa Rica
View Trial DetailsNCT07642544
Psoriasis, Psoriasis (PsO)
Nanjing, Jiangsu, China
View Trial DetailsNCT06846541
Moderate Psoriasis, Plaque Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT07149792
Arthritis, Arthritis, Psoriatic
Taichung, Taiwan
View Trial Details